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Lyon F-69007, FranceHepatitis C virus (HCV) is a positive strand RNA virus forming the
genus Hepacivirus in the Flaviviridae family. Replication of HCV
starts with the virus binding to hepatocytes, which are the pri-
mary, if not exclusive host cells. HCV entry is a multi-step and
slow process (Panel 1). Interactions between HCV E1–E2 enve-
lope glycoproteins and glycosaminoglycans (GAGs) contribute
to primary binding of the virus particles to host cells. Owing to
the association of HCV with (very) low-density-lipoproteins
[(V)LDL] [1], the LDL receptor (LDLr) has also been proposed as
a capture molecule. Upon this initial engagement, the scavenger
receptor BI (SR-BI), the CD81 tetraspanin, together with the tight
junction proteins Claudin-1 (CLDN-1) and Occludin (OCLN) syn-
ergistically contribute to HCV uptake in a clathrin-dependent
manner [2]. Additional serum factors, e.g., high-density-lipopro-
tein, promote entry by increasing uptake kinetics through
interaction with SR-BI [3]. HCV entry appears to occur in a pH-
dependent manner, whereby the low endosomal pH induces con-
formational rearrangement of HCV glycoproteins, leading to
fusion of the viral and endosomal membranes and subsequent
uncoating.
Viral RNA released into the cytoplasm is translated via an
internal ribosome entry site (IRES) located in the 50 non-trans-
lated region of the genome [4] (Panel 2). RNA translation occurs
at the rough endoplasmic reticulum (ER) giving rise to a 3000
amino acid long polypeptide that is cleaved into 10 different
products. The region from the core to the C-terminus of p7 is pro-
cessed by host cell signal peptidases whereas the remainder is
cleaved by two viral enzymes: (i) a cysteine protease residing
in nonstructural protein 2 (NS2) that cleaves between NS2 and
NS3, (ii) the NS3 serine protease that is activated by interaction
with NS4A and that catalyzes processing at all other sites within
the NS-region. An additional processing in the C-terminal region
of the core protein is mediated by signal peptide peptidase, which
is required to mobilize core protein for translocation to lipid
droplets (LDs). In addition to the polypeptide, core protein deriv-
atives (designated mini-cores and core+1 proteins) with
unknown function are generated by alternative translation
mechanisms.Journal of Hepatology 20
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ciated with ER-derived membranes (Panel 3) where they have to
exert their function, including theNS3-mediated cleavage of cellu-
lar molecules required for signaling of innate immune responses
(reviewed in [5]). Primarily by the action of NS4B, presumably in
conjunction with NS5A, membranous replication vesicles (RVs)
are induced and accumulate in the infected cell as distinct struc-
tures designated as the membranous web (Panel 4). This web in
addition contains ER membranes and LDs. It is the site where viral
RNA is ampliﬁed by the NS5B RNA-dependent RNA polymerase
(RdRp) in conjunction with most, if not all other NS proteins and
host cell factors such as cyclophilin A. By analogy to ﬂaviviruses
[6], RNA replication may occur in invaginations of the ER mem-
brane in a semi-conservative and asymmetric manner (Panel 5).
The positive strand genome is copied into a negative strand RNA
via a replicative form (RF) that is used for the synthesis of excess
amounts of positive strand RNAs via a replicative intermediate
(RI). Initiation of RNA synthesis requires highly structured RNA
elements in the 30 NTRof the corresponding template strand (Panel
2). Newly synthesized RNA genomes are used for translation (pro-
duction of new viral proteins), RNA replication, or formation of
new infectious virions (assembly). The latter event place in close
proximity of LDswhere the core protein accumulates almost quan-
titatively (Panel 6). Viral RNA is thought to be delivered from rep-
lication sites to the core protein on LDs by the viral replicase [7].
Alternatively, NS5A, which has an intrinsic RNA binding capacity,
may be released from the replicase complex to move onto the LD
surface. Via a core–NS5A interaction, RNA could be delivered to
the core protein thus triggering nucleocapsid formation. These
capsids may bud into the ER lumen in a process that is tightly
linked to VLDL synthesis [8]. Thus, HCV assembly very much
depends on (V)LDL synthesis and requires several enzymes such
a microsomal triglyceride transfer protein (MTP), but also apoE.
This assembly pathway would explain the (V)LDL-like composi-
tion of HCV particles [1] and the incorporation of apoE (Panel 7).
Whether apoB is required for HCV assembly is discussed contro-
versially. It is not known whether HCV particles have a regular
nucleocapsid or an unstructured core protein–RNA complex.
Major efforts are undertaken to develop selective antiviral
drugs [9]. Thus far, most compounds target the NS3 protease,
the NS5B RdRp and NS5A, a RNA binding phosphoprotein
required for RNA replication and assembly. Inhibition of the
NS3 protease blocks polypeptide cleavage and thus formation
of new replication sites, but probably does not affect already
established replication complexes. In contrast, nucleosides and
non-nucleosidic inhibitors, blocking the NS5B RdRp, most likely10 vol. 53 j 583–585
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affect activity of existing replication complexes. How compounds
targeting NS5A interfere with HCV replication is unknown.Conﬂicts of interest
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